PMEL and neoplasm: For further evidence of tumor reactivity, we have used two additional batches of HLA-A2 tumor-bearing Hu-mice and show that CDR3/TCR sequences predict and suggestive of diverse reactivity to melanoma differentiation antigens (MART-1 and gp100) and cancer-testis antigens (MAGE A1 and NY-ESO-1) in the spleen.